Search Results - "Blight, Andrew R"

Chondroitinase improves anatomical and functional outcomes after primate spinal cord injury by Rosenzweig, Ephron S., Salegio, Ernesto A., Liang, Justine J., Weber, Janet L., Weinholtz, Chase A., Brock, John H., Moseanko, Rod, Hawbecker, Stephanie, Pender, Roger, Cruzen, Christina L., Iaci, Jennifer F., Caggiano, Anthony O., Blight, Andrew R., Haenzi, Barbara, Huie, J. Russell, Havton, Leif A., Nout-Lomas, Yvette S., Fawcett, James W., Ferguson, Adam R., Beattie, Michael S., Bresnahan, Jacqueline C., Tuszynski, Mark H.

“…Inhibitory extracellular matrices form around mature neurons as perineuronal nets containing chondroitin sulfate proteoglycans that limit axonal sprouting…”
Get full text

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial by Goodman, Andrew D, Prof, Brown, Theodore R, MD, Krupp, Lauren B, MD, Schapiro, Randall T, MD, Schwid, Steven R, MD, Cohen, Ron, MD, Marinucci, Lawrence N, MS, Blight, Andrew R, PhD

“…Summary Background Clinical studies suggested that fampridine (4-aminopyridine) improves motor function in people with multiple sclerosis. This phase III study…”
Get full text

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial by Applebee, Angela, MD, Goodman, Andrew D., MD, Mayadev, Angeli S., MD, Bethoux, Francois, MD, Goldman, Myla D., MD, MSc, Klingler, Michael, MPH, Blight, Andrew R., PhD, Carrazana, Enrique J., MD

“…Abstract Purpose Dalfampridine extended-release (ER) tablets 10 mg BID have been approved for use in improving walking in people with multiple sclerosis (MS)…”
Get full text

A grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury by Kwon, Brian K, Okon, Elena B, Tsai, Eve, Beattie, Michael S, Bresnahan, Jacqueline C, Magnuson, David K, Reier, Paul J, McTigue, Dana M, Popovich, Phillip G, Blight, Andrew R, Oudega, Martin, Guest, James D, Weaver, Lynne C, Fehlings, Michael G, Tetzlaff, Wolfram

“…The past three decades have seen an explosion of research interest in spinal cord injury (SCI) and the development of hundreds of potential therapies that have…”
Get more information

Chondroitinase ABCI improves locomotion and bladder function following contusion injury of the rat spinal cord by Caggiano, Anthony O, Zimber, Michael P, Ganguly, Anindita, Blight, Andrew R, Gruskin, Elliott A

“…Chondroitin sulfate proteoglycans are synthesized and deposited in the spinal cord following injury. These proteoglycans may restrict regeneration and…”
Get more information

Safety, Tolerability, and Sensorimotor Effects of Extended-Release Dalfampridine in Adults With Cerebral Palsy: A Pilot Study by Bethoux, Francois, MD, Fatemi, Ali, MD, Fowler, Eileen, PhD, Marciniak, Christina, MD, Mayadev, Angeli, MD, Waksman, Joel, PhD, Zackowski, Kathleen, PhD, Suarez, Gustavo, MD, Blight, Andrew R., PhD, Rabinowicz, Adrian L., MD, Carrazana, Enrique, MD

“…Abstract Purpose The goal of this study was to evaluate the safety and tolerability of dalfampridine extended release (D-ER) in a pilot study of adults with…”
Get full text

The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials by Cornblath, David R., MD, Bienen, E. Jay, PhD, Blight, Andrew R., PhD

“…Abstract Background Dalfampridine (fampridine outside the United States) is a broad-spectrum potassium channel blocker. Dalfampridine extended-release tablets…”
Get full text

Timed 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS by HOBART, Jeremy, BLIGHT, Andrew R, GOODMAN, Andrew, LYNN, Frances, PUTZKI, Norman

“…In this study, we used data from clinical trials of dalfampridine (fampridine outside the United States) to re-examine the clinical meaningfulness of Timed…”
Get full text

Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-Release 10-mg tablets in patients with multiple sclerosis: A 2-week, open-label, follow-up study by Vollmer, Timothy, MD, Blight, Andrew R., PhD, Henney, Herbert R., PharmD

“…Abstract Background: Fampridine sustained release (SR) has generally been well tolerated in clinical studies in patients with multiple sclerosis (MS) at doses…”
Get full text

Treatment of walking impairment in multiple sclerosis with dalfampridine by Blight, Andrew R.

“…Potassium channel blockade has long been considered a potential therapeutic strategy for treatment of multiple sclerosis (MS) based on the pathophysiology of…”
Get full text

Effect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteers by Henney, 3rd, Herbert R, Faust, Bonnie, Blight, Andrew R

“…The pharmacokinetics, bioavailability, and tolerability of dalfampridine extended-release tablets in healthy adults under fed and fasted conditions were…”
Get full text

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis by Goodman, Andrew D., Brown, Theodore R., Edwards, Keith R., Krupp, Lauren B., Schapiro, Randall T, Cohen, Ron, Marinucci, Lawrence N., Blight, Andrew R.

“…Objective A previous phase 3 study showed significant improvement in walking ability in multiple sclerosis (MS) patients treated with oral, extended‐release…”
Get full text

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine by Hobart, Jeremy, Ziemssen, Tjalf, Feys, Peter, Linnebank, Michael, Goodman, Andrew D., Farrell, Rachel, Hupperts, Raymond, Blight, Andrew R., Englishby, Veronica, McNeill, Manjit, Chang, Ih, Lima, Gabriel, Elkins, Jacob

“…Background Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively…”
Get full text

4-chloro-3-hydroxyanthranilate reduces local quinolinic acid synthesis, improves functional recovery, and preserves white matter after spinal cord injury by Yates, Jennifer R, Heyes, Melvyn P, Blight, Andrew R

“…Inflammatory processes within the central nervous system (CNS) contribute significantly to the pathogenesis of a broad range of neurologic diseases, including…”
Get more information

The challenge of recruitment for neurotherapeutic clinical trials in spinal cord injury by Blight, Andrew R., Hsieh, Jane, Curt, Armin, Fawcett, James W., Guest, James D., Kleitman, Naomi, Kurpad, Shekar N., Kwon, Brian K., Lammertse, Daniel P., Weidner, Norbert, Steeves, John D.

“…Study design Narrative review by individuals experienced in the recruitment of participants to neurotherapeutic clinical trials in spinal cord injury (SCI)…”
Get full text

Targeting Translational Successes through CANSORT-SCI: Using Pet Dogs To Identify Effective Treatments for Spinal Cord Injury by Moore, Sarah A, Granger, Nicolas, Olby, Natasha J, Spitzbarth, Ingo, Jeffery, Nick D, Tipold, Andrea, Nout-Lomas, Yvette S, da Costa, Ronaldo C, Stein, Veronika M, Noble-Haeusslein, Linda J, Blight, Andrew R, Grossman, Robert G, Basso, D Michele, Levine, Jonathan M

“…Translation of therapeutic interventions for spinal cord injury (SCI) from laboratory to clinic has been historically challenging, highlighting the need for…”
Get more information

Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis by Blight, Andrew R., Henney III, Herbert R., Cohen, Ron

“…Walking impairment is a clinical hallmark of multiple sclerosis (MS). Dalfampridine‐ER, an extended‐release formulation of dalfampridine (also known by its…”
Get full text

Data Safety Monitoring Boards: Overview of Structure and Role in Spinal Cord Injury Studies by Blight, Andrew R, Guest, James D, Hamer, James, Hsieh, Jane T C, Jones, Linda, Magnuson, David S K, Pfleeger, Kimberley

“…This paper provides an overview of the history, composition, organization, responsibilities, and regulatory requirements of Data Safety Monitoring Boards…”
Get full text

Lower extremity outcome measures: considerations for clinical trials in spinal cord injury by Bolliger, Marc, Blight, Andrew R., Field-Fote, Edelle C., Musselman, Kristin, Rossignol, Serge, Barthélemy, Dorothy, Bouyer, Laurent, Popovic, Milos R., Schwab, Jan M., Boninger, Michael L, Tansey, Keith E., Scivoletto, Giorgio, Kleitman, Naomi, Jones, Linda A. T., Gagnon, Dany H., Nadeau, Sylvie, Haupt, Dirk, Awai, Lea, Easthope, Chris S, Zörner, Björn, Rupp, Ruediger, Lammertse, Dan, Curt, Armin, Steeves, John

“…Study Design This is a focused review article. Objectives To identify important concepts in lower extremity (LE) assessment with a focus on locomotor outcomes…”
Get full text

Experimental Treatments for Spinal Cord Injury: What you Should Know by Failli, Vieri, Kleitman, Naomi, Lammertse, Daniel P, Hsieh, Jane T C, Steeves, John D, Fawcett, James W, Tuszynski, Mark H, Curt, Armin, Fehlings, Michael G, Guest, James D, Blight, Andrew R

“…The information provided focuses mostly on testing of new drugs, cellular therapies, tissue or cells used as grafts, antibodies or other biological substances,…”
Get full text